, Tracking Stock Market Picks
Enter Symbol:
Brainstorm Cell Therapeutics Inc(NDA) (BCLI) [hlAlert]

down 36.61 %

Brainstorm Cell Therapeutics Inc(NDA) (BCLI) rated Buy with price target $5 by Maxim Group

Posted on: Tuesday,  Dec 22, 2015  8:25 AM ET by Maxim Group

Maxim Group rated Buy Brainstorm Cell Therapeutics Inc(NDA) (NASDAQ: BCLI) on 12/22/2015. Previously Maxim Group rated Buy Brainstorm Cell Therapeutics Inc(NDA) (NASDAQ: BCLI)
on 07/30/2014., when the stock price was $4.58. Since then, Brainstorm Cell Therapeutics Inc(NDA) has lost 36.61% as of 12/22/2015's recent price of $2.90.
If you would have followed the previous Maxim Group's recommendation on BCLI, you would have lost 36.61% of your investment in 510 days.

Brainstorm Cell Therapeutics Inc. (Brainstorm) is a development-stage company. The Company is engaged in developing stem cell therapeutic products based on technologies enabling the in-vitro differentiation of bone marrow stem cells to neural-like cells. The Company focuses on utilizing the patient?s own bone marrow stem cells to generate neurotrophic factors (NTF) cells that may provide treatment for amyotrophic lateral sclerosis (ALS), parkinson?s disease (PD) and spinal cord injury. The Company?s technology is based on the NurOwn products, an autologous cell therapeutic modality, consisting of the extraction of the patient bone marrow, processed into neuronal-like cells and re-implanted into the patient?s muscles or brain.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2015 8:25 AM Buy
2.70 5.00
as of 8/27/2015
1 Week up  2.83 %
1 Month down  -22.04 %
3 Months down  -21.62 %
1 YTD down  -36.61 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/30/2014 12:00 AM Buy
4.58 45.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy